Smolka Grzegorz, Pysz Piotr, Wojakowski Wojciech, Ochała Andrzej, Peszek-Przybyła Ewa, Roleder Tomasz, Jasinski Marek, Gasior Zbigniew
3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland.
J Invasive Cardiol. 2013 May;25(5):226-31.
To evaluate the transcatheter paravalvular leak closure (TPVLC) aptitude to reduce manifestations of heart failure caused by aortic paravalvular leak (PVL).
TPVLC is a valuable alternative to reoperation. While technical feasibility of the method is well established, data on long-term clinical outcome are less abundant.
We launched a prospective registry of patients with clinically significant aortic PVL. They were scheduled for TPVLC with Amplatzer vascular plug (AVP) II and III devices serving as occluders. The efficacy and safety were monitored at 6-month follow-up exam.
The occluder deployment reached a success rate of nearly 90%. Following the procedure, we recorded significant improvement both in terms of patient functional capacity and echocardiographic determinants of left ventricular performance. Simultaneously, NT-proBNP plasma concentration and hemolysis markers decreased. Only local complications related to puncture site occurred.
Heart failure caused by aortic PVL can be safely and efficiently treated with TPVLC using AVP II and III devices as occluders.
评估经导管瓣膜旁漏封堵术（TPVLC）减少主动脉瓣旁漏（PVL）所致心力衰竭表现的能力。
TPVLC是再次手术的一种有价值的替代方法。虽然该方法的技术可行性已得到充分证实，但关于长期临床结果的数据较少。
我们启动了一项针对具有临床意义的主动脉PVL患者的前瞻性登记研究。他们计划使用Amplatzer血管封堵器（AVP）II型和III型装置作为封堵器进行TPVLC。在6个月的随访检查中监测疗效和安全性。
封堵器置入成功率接近90%。术后，我们记录到患者的功能能力和左心室功能的超声心动图指标均有显著改善。同时，NT-proBNP血浆浓度和溶血标志物下降。仅发生了与穿刺部位相关的局部并发症。
使用AVP II型和III型装置作为封堵器的TPVLC可安全有效地治疗主动脉PVL所致的心力衰竭。
